Stakeholders take issue with FDA’s guidance on drugs with mutagenic potential
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsFerdous Al-FaruqueBiologics/ biosimilars/ vaccinesGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)